Phase II RCT in 120 men with PSMA-positive mCRPC after abiraterone: 131I-LNTH-1095 plus enzalutamide vs enzalutamide alone raised PSA50 response (62.9% vs 31.3%; P=0.003), but grade ≥3 adverse events were more frequent (65.8% vs 41%).
RCTn = 120
Yu et al. 131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study